U.S. Hemophilia Treatment Market Set for Substantial Growth Due to Rising Prevalence of Genetic Bleeding Disorders

The U.S. hemophilia treatment market comprises biologics and non-biologics drugs that are used in the treatment of hemophilia A and hemophilia B. Hemophilia is a rare genetic bleeding disorder characterized by prolonged bleeding due to the deficiency of blood clotting factors such as Factor VIII and Factor IX. Biologics drugs are recombinant and plasma-derived and include factor VIII and factor IX products. Non-biologics drugs are desmopressin products that raise clotting factor levels in patients with mild hemophilia A or von Willebrand disease. Non-biologics drugs are cheaper alternatives to biologics but are less effective.

U.S. hemophilia treatment market size is expected to reach US$ 6.81 Bn by 2031, from US$ 4.21 Bn in 2023, exhibiting a compound annual growth rate (CAGR) of 6.2% during the forecast period.

Key Takeaways

Key players operating in the U.S. hemophilia treatment market are Takeda Pharmaceutical Company Limited, Sanofi, Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., and Biogen Inc. Takeda dominates the market with its flagship brands such as ADVATE and FEIBA.

The U.S. Hemophilia Treatment Market Trends offers lucrative growth opportunities for players to develop novel drug delivery systems, gene therapies, and extended half-life factor replacement therapies. Several biotechs are conducting clinical trials for innovative gene therapies that can cure hemophilia with a single administration.

Leading market players are expanding globally by acquiring regional pharmas, establishing manufacturing facilities, and boosting their commercial infrastructures. Takeda acquired Shire to boost its hemophilia franchise globally. Emerging countries present ample opportunities due to growing diagnosis rates and increasing healthcare spends.

Market Drivers
Rising prevalence of genetic bleeding disorders - According to Center for Disease Control and Prevention (CDC), around 1 in 5,000 males in the U.S. are affected by hemophilia. This high prevalence is expected to drive the hemophilia treatment market.

Increasing adoption of prophylactic treatment - Prophylactic treatment is designed to prevent bleeds by regularly infusing clotting factor concentrates. It is becoming the standard of care as it can prevent long-term complications like joint damage and improve quality of life.

Market Restrains

High cost of biologics drugs - Biologics drugs are very expensive ranging between US$ 100,000 - 300,000 per year for hemophilia A and B patients. This increases the economic burden on patients, limiting accessibility.

Shortage of clotting factor therapies - Supply chain issues frequently lead to shortages of clotting factor products in the U.S. market, restricting treatment availability at times.

Segment Analysis
The U.S. hemophilia treatment market is dominated by the Hemophilia A sub-segment. Hemophilia A accounts for around 80% of the cases of hemophilia diagnosed in the U.S. each year. It is caused due to a genetic defect leading to deficiency of clotting factor VIII in the blood. Without treatment, it can cause painful internal bleeding in muscles and joints. The high prevalence of Hemophilia A makes it the dominant sub-segment driving the overall market growth.

Global Analysis
The North America region dominates the global hemophilia treatment market and is expected to continue its dominance during the forecast period. This is attributed to the growing patient awareness regarding advanced treatment options and frequent launches of novel treatment therapies in the region. In addition, primary key players such as Takeda, Sanofi, Pfizer, and Baxter International have their headquarters located in North America, which offers advanced hemophilia care services and products to patients. The high healthcare expenditure along with strategic presence of market leaders further supplements the market growth in this region.

Get this Report in Japanese Language: 米国の血友病治療市場

Get this Report in Korean Language: 미국혈우병치료시장

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )